These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10140524)

  • 1. Changes in effectiveness of psychotherapeutic drug level monitoring program after lessening pharmacy involvement.
    Cyr M; Dorson PG; Crismon ML
    Hosp Pharm; 1995 Feb; 30(2):116, 118-9. PubMed ID: 10140524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interaction monitoring program in a community hospital.
    Cramer RL; Sketo DV; Greene JL; Wright CA
    Am J Hosp Pharm; 1992 Mar; 49(3):627-9. PubMed ID: 1598942
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of a clinical psychopharmacy consultation service on patient outcomes.
    Stanislav SW; Barker K; Crismon ML; Childs A
    Am J Hosp Pharm; 1994 Mar; 51(6):778-81. PubMed ID: 8010316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
    Baumann P; Hiemke C; Ulrich S; Eckermann G; Gaertner I; Gerlach M; Kuss HJ; Laux G; Müller-Oerlinghausen B; Rao ML; Riederer P; Zernig G;
    Pharmacopsychiatry; 2004 Nov; 37(6):243-65. PubMed ID: 15551191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of plasma assays of psychotropic drugs].
    François T; Bonin B; Vandel S; Sechter D; Bizouard P
    Rev Prat; 1994 Nov; 44(17):2336-40. PubMed ID: 7984943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of managerial intervention on drug utilization pattern at King Chulalongkorn Memorial Hospital.
    Limpanasithikul W; Wangsaturaka D; Nantawan P; Itthipanichapong C; Thamaree S; Wittayalertpanya S; Ketcharoen A; Taworn N; Kemsri W; Kusolsomboon T; Tangphao O
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S336-43. PubMed ID: 12188432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations.
    Alldredge BK
    Neurology; 1999; 53(5 Suppl 2):S68-75. PubMed ID: 10496236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical psychopharmacy consultations: acceptance of recommendations on an adult inpatient psychiatric unit.
    Morton WA; Mendenhall AR; Windsor PG; Lydiard B
    Hosp Pharm; 1995 Sep; 30(9):786-90. PubMed ID: 10151283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of drug decisions in a state psychiatric hospital.
    Gillis JS; Moran TJ
    J Clin Psychol; 1981 Jan; 37(1):32-42. PubMed ID: 6110676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypharmacy in psychiatry: a multi-state comparison of psychotropic drug combinations.
    Sheppard C; Beyel V; Fracchia J; Merlis S
    Dis Nerv Syst; 1974 Apr; 35(4):183-9. PubMed ID: 17894114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics.
    Pichini S; Papaseit E; Joya X; Vall O; Farré M; Garcia-Algar O; de laTorre R
    Ther Drug Monit; 2009 Jun; 31(3):283-318. PubMed ID: 19363463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood dyscrasias induced by psychotropic drugs.
    Stübner S; Grohmann R; Engel R; Bandelow B; Ludwig WD; Wagner G; Müller-Oerlinghausen B; Möller HJ; Hippius H; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S70-8. PubMed ID: 15052517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital pharmacists' activities and attitudes regarding the Thai safety monitoring program for new drugs.
    Jarernsiripornkul N; Krska J; Pongmanachai M; Nasritha N
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):837-41. PubMed ID: 19548223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs.
    Hendset M; Haslemo T; Rudberg I; Refsum H; Molden E
    Pharmacopsychiatry; 2006 Jul; 39(4):121-7. PubMed ID: 16871467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical monitoring guidelines for neuroleptic and antidepressant drugs. Central State Hospital, Milledgeville, Georgia.
    Holbrook JM; Parks-Veal P; Mimbs J
    Hosp Pharm; 1991 Sep; 26(9):783-4, 787-93. PubMed ID: 10136553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic drug monitoring (TDM) of psychotropic drugs: a consensus guideline of the AGNP-TDM group].
    Baumann P; Hiemke C; Ulrich S; Eckermann G; Kuss HL; Laux G; Müller-Oerlingenhausen B; Rao ML; Riederer P; Zernig G; ;
    Rev Med Suisse; 2006 May; 2(67):1413-8, 1420-2, 1424-6. PubMed ID: 16786958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study.
    Grohmann R; Engel RR; Geissler KH; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S27-38. PubMed ID: 15052512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.